Two professors of Escola Paulista de Medicina (São Paulo Medicine School), Drs. Humberto Delboni and Raul Dias dos Santos founded the Médicos Associados em Patologia Clínica (MAP) (Associate Physicians in Clinical Pathology) in the city of São Paulo.

Dr. Caio Auriemo joined the company and it changed its name to Laboratório Clínico Delboni Auriemo S/C Ltda.

The Company became known as Delboni Auriemo and started the process of modernizing its patient centers.

The company became Diagnósticos da América S.A. and presented its new brand and new name, Dasa. In the 2000s, Dasa acquired laboratories in Brazil, such as: Bornstein, Pasteur, Lâmina, Image Memorial, Atalaia and others.

Dasa completed its IPO at BM&FBOVESPA (current B3).

The Bueno family acquired 24% of the outstanding shares, setting the onset of the New Dasa – its name referring to the period after the entry of current controlling shareholders.

The holding Cromossomo II, jointly with its indirect controlling shareholders, Mr. Edson de Godoy Bueno and Mrs. Dulce Pugliese de Godoy, became Dasa’s majority shareholder, holding 71.94% of the Company’s capital stock.

The Bueno family took the helm of New Dasa on January 16, 2015, as Mr. Pedro de Godoy Bueno became the Company’s CEO.

At the Alphaville processing center (NTO), Dasa implemented the world’s largest medical test processing facility.

Cromossomo II, jointly with Mr. Edson de Godoy Bueno and Mrs. Dulce Pugliese de Godoy Bueno, reached a total of 97.79% of the Company’s capital. Shares ceased to be traded on the Novo Mercado and were traded at BM&FBOVESPA’s traditional segment (current B3).

Dasa ramped up its health ecosystem strategy.

The Company’s board of directors approved the proposal to increase the Company’s capital stock via the assignment of 100% shares issued to Ímpar Serviços Hospitalares S.A., a network composed of seven high-complexity hospitals, which included Hospital 9 de Julho (São Paulo), Hospital Águas Claras (Brasília) and Complexo Hospitalar de Niterói (Niterói, RJ).

Dasa advanced on structuring its integrated health network, composed of outpatient care, diagnostics, hospitals, and care coordination.

The Emergency Diagnostics Center (CDE): in partnership with the Ministry of Health, Dasa donated labor and infrastructure to handle up to three million Covid-19 RT-PCR tests.

Dasa acquired GSC, a benchmark company in care coordination and health management; an integrator with 20-years of experience and with proven results in end-to-end users’ healthcare.

Dasa raised R$3.3 billion funds in a primary offer held in April to bolster its integrated network strategy.

Dasa’s request to migrate to B3’s Novo Mercado special listing segment was accepted, the Company’s shares were then traded on Novo Mercado as of June 2021.

Dasa acquired hospitals with over 1,500 beds, ranking as Brazil’s second-largest private hospital group.

Nav was launched as the digital platform that connects patients and physicians, with an intuitive and data-based experience, which saw exponential users growth.

Dasa Empresas improved its offer of a Business Intelligence platform for businesses’ human resources areas and greater performance in benefits advisory services.